Join Transgene for a virtual event to discuss new Phase I immunological data presented at SITC 2025 that support the individualized neoantigen therapeutic vaccine TG4050’s potential role in preventing cancer relapse. This event will offer important scientific and clinical context around the latest findings and outline how TG4050 continues to distinguish itself within the rapidly evolving neoantigen vaccine field.

The event will provide an overview of TG4050’s ability to induce potent neoantigen-specific cytotoxic CD8+ T-cell responses capable of recognizing and eliminating tumor cells. Management will highlight evidence of durable, functional T-cell activity that reinforces TG4050’s potential to deliver sustained immune surveillance and reduce risk of relapse when used as single agent in the adjuvant treatment of HPV-negative operable head and neck cancer patients.

Additional discussion will focus on the broader implications for the ongoing Phase I/II clinical program, upcoming milestones, and how this dataset informs future development strategy.

A live question and answer session will follow the formal presentations.